Novartis loses appeal to block generic Entresto launch
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the ...
Shares of Divi's Laboratories Ltd. are down by up to 6% on Thursday, December 5, following Novartis losing its appeal in a US ...
Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1bn, enhancing its ...
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...